0000000000644757

AUTHOR

Nicolas Peschanski

0000-0003-3757-9733

showing 2 related works from this author

Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of…

2021

International audience; INTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) is a prognostic biomarker of cardiovascular disease. OBJECTIVES: We aimed to evaluate the early prognostic value of suPAR in patients presenting to the emergency department (ED) with chest pain suggestive of acute coronary syndrome (ACS). PATIENTS AND METHODS: In a post-hoc analysis from a multicenter study including patients with a chest pain < 6 h, suPAR concentrations at ED admission were studied according to the outcome at 30-days. RESULTS: 198 patients (median age 56 years) in whom 16% had an ACS, were included. Fifteen (7.3%) patients presented a 30-day event. At ED admission, median (IQR…

AdultMale030213 general clinical medicineAcute coronary syndromemedicine.medical_specialty[SDV]Life Sciences [q-bio]Clinical BiochemistrySoluble urokinase plasminogen activator receptorDisease030204 cardiovascular system & hematologyChest painPrognosticGastroenterologyReceptors Urokinase Plasminogen ActivatorsuPARChest pain03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumansIn patientAcute Coronary SyndromeReceptorAgedOutcomeAged 80 and overbusiness.industryEmergency departmentGeneral MedicineEmergency departmentMiddle Agedmedicine.diseasePrognosisED30-day event3. Good health[SDV] Life Sciences [q-bio]SuPARBiomarker (medicine)Femalemedicine.symptombusinessEmergency Service HospitalBiomarkers
researchProduct

Is high-sensitivity troponin, alone or in combination with copeptin, sensitive enough for ruling out NSTEMI in very early presenters at admission? A …

2019

Objectives: Copeptin and high-sensitivity cardiac troponin (HS-cTn) assays improve the early detection of non-ST-segment elevation myocardial infarction (NSTEMI). Their sensitivities may, however, be reduced in very early presenters.Setting: We performed a post hoc analysis of three prospective studies that included patients who presented to the emergency department for chest pain onset (CPO) of less than 6 hours.Participants: 449 patients were included, in whom 12% had NSTEMI. CPO occurred 4 hours in 146 patients. The prevalence of NSTEMI was similar in all groups (9%, 13% and 12%, respectively, p=0.281).Measures: Diagnostic performances of HS-cTn and copeptin at presentation were examined…

MaleTime Factors030204 cardiovascular system & hematologyChest pain0302 clinical medicinehigh sensitive cardiac troponinTroponin IMedicine1506Prospective Studies030212 general & internal medicineMyocardial infarctionNon-ST Elevated Myocardial InfarctionProspective cohort studynon st-elevation acute myocardial infarction[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTroponin TRGlycopeptidesGeneral MedicineMiddle Aged3. Good healthchest pain onsetEmergency MedicineCardiologyMedicineFemalevery early presentersmedicine.symptomEmergency Service HospitalAdultmedicine.medical_specialtychest pain03 medical and health sciencesCopeptinPredictive Value of TestsInternal medicinePost-hoc analysisHumansAgedbusiness.industryResearchTroponin IcopeptinEmergency departmentmedicine.disease1691businessBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct